| Literature DB >> 24949448 |
Qing Jiao1, Liwen Li1, Qingxin Mu2, Qiu Zhang1.
Abstract
Nanoparticles (NPs) have promising applications in medicine. Immune system is an important protective system to defend organisms from non-self matters. NPs interact with the immune system and modulate its function, leading to immunosuppression or immunostimulation. These modulating effects may bring benefits or danger. Compositions, sizes, and surface chemistry, and so forth, affect these immunomodulations. Here we give an overview of the relationship between the physicochemical properties of NPs, which are candidates to be applied in medicine, and their immunomodulation properties.Entities:
Mesh:
Year: 2014 PMID: 24949448 PMCID: PMC4052466 DOI: 10.1155/2014/426028
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Figure 1The immunomodulation of NPs presents a Janus' double-face in nanomedicine applications. On one hand, the effects to the immune system may benefit treatment of disease through enhancing immune response. On the other hand, the immunomodulation of NPs may bring harm.
Immunomodulation of various nanoparticles in nanomedicine applications.
| Nanomaterial | Size | Exposure routes/doses | Outcomes | Cytokines/chemokines | Animal | Reference |
|---|---|---|---|---|---|---|
| Carbon nanotube | ||||||
| MWCNT | L: 5–15 | Inhalation 5 mg/m3
| Immunosuppression | TGF | Male C57BL/6 | [ |
| D: 10–20 nm | ||||||
| SWCNT | L: 1–3 | Pharyngeal aspiration 40, 80, 120 | Inflammation immunosuppression | TNF- | Female BALB/c and C57BL/6 |
[ |
| D: 1–4 nm | ||||||
| MWCNT | L: several | Oropharyngeal aspiration 1, 2, and 4 mg/kg | Inflammation | IL-33↑, CCL3↑, CCL11↑ | C57BL/6 |
[ |
| D: 12.5–25 nm | ||||||
| MWCNT | L: several | Oropharyngeal aspiration 4 mg/kg | Inflammation | IL-33↑, IL-5↑, IL-8↑, IL-13↑ | C57BL/6 |
[ |
| D: 12.5–25 nm | ||||||
| MWCNT | L: 15 ± 5 | Intravenously 1 mg/kg | Inflammation | IL-4↑, IL-33↑ | C57BL/6 |
[ |
| D: 25 ± 5 nm | ||||||
| MWCNT | L: 50 | Subcutaneous 0.05, 0.3, and 0.5 mg × 2/mouse | Acute inflammation | IL-17↑, IL-1 | BALB/c |
[ |
| D: 20–30 nm | ||||||
| MWCNT | L: 0.3–50 | Inhalation | Hypersensitivity | PDGF-AA↑, TGF- | Allergic asthma mice (C57BL/6) |
[ |
| D: 30–50 nm | ||||||
| SWCNT | L: 3–30 | Intratracheal 25, 50 | Hypersensitivity | IL-4↑, IL-5↑, IL-13↑, IFN- | Allergic inflammation mice (male ICR) |
[ |
| D: 67 nm | ||||||
|
| ||||||
| Graphene | ||||||
| Graphene | 4 ± 1 | Intravenously 1 mg/kg | Activate Th2 immune response | IL-33↑, IL-5↑, IL-13↑ | C57BL/6 |
[ |
| 2 ± 1 nm thick | ||||||
|
| ||||||
| Fullerene | ||||||
| C60 | N/A | Intravenously 50 ng/mouse | Immunosuppression | Serum histamine↓, Lyn↓, Syk↓, ROS↓ | MC-dependent model of anaphylaxis (C57BL/6) | [ |
| C60 | N/A | Intra-articular treatment 10.0 | Immunosuppression | TNF- | Rat model of arthritis (female Sprague-Dawley rats) | [ |
| C60 | N/A | Instillation 2 mg/kg | Inflammation | IL-1↑, TNF- | Male ICR | [ |
| Carboxyfullerene | N/A | Peritoneum and air pouch 40 mg/kg | Activate immune system | N/A | C57BL/6 | [ |
| Hydroxylated C60 | N/A | Intraperioneally injection 2 | Immunosuppression | IL-11↑, elastase2 gene↓ | Fathead minnow | [ |
| C60 | N/A | Intraperitoneal injection 0.5 mL × 10 | Immunosuppression | IFN- | Tumor-bearing mice (C57BL/6) | [ |
|
| ||||||
| Gold nanoparticles | ||||||
| PfMSP-119/PvMSP-119 coated GNPs formulated with alum | 17 nm | Subcutaneously 25 | Immunogenic | Antibody titer↑ | BALB/c | [ |
| PfMSP-119/PvMSP-119 coated GNPs | 17 nm | Subcutaneously 25 | Poor immunogenic | N/A | BALB/c | [ |
| Short-chain PEG mixed-monolayer protected gold clusters | <5 nm | Subcutaneously injection 40 | Immunogenic | Antibody titer↑ | BALB/cAnNHsd | [ |
| PEG coated GNP | 13 nm | Intravenously 0, 0.17, 0.85 or 4.26 mg/kg | Acute inflammation | MCP-1/CCL-2↑, MIP-1 | BALB/c | [ |
| GNP functionalized with 2-mercaptoethanesulfonic acid (MES) or N,N,N-trimethylammoniumethanethiol (TMAT) | 1.5 nm | Media exposure 0.016–250 ppm | Activate immune response Inflammatory response | Il-5↓, IL-12↓, IL-15↓, IL-18↓ | Zebrafish embryos | [ |
| Citrate-stabilized GNPs | 40 nm | Oropharyngeal aspiration 0.8 mg/kg | Hypersensitivity | MMP-9↑, MIP-2↑, TNF- | TDI-sensitised mice (BALB/c) | [ |
| GNP | 21 nm | Intraperitoneally injection 7.85 | Antiflammatory | TNF- | Male C57BL/6 | [ |
| Citrate-stabilized GNPs | 5 nm | 100 nmol Au/kg | Antiflammatory | IL-1 | IL-1 | [ |
|
| ||||||
| Silver Nanoparticles | ||||||
| AgNP | 22.18 ± 1.72 nm | Inhalation 1.91 × 107 particles/cm3 × 6 h/day × 5 days/week × 2 weeks | Immunosuppression | Malt1 gene↓, Sema7a gene↓ | C57BL/6 | [ |
| AgNP | 52.25 ± 23.64 nm | Intratracheal instillation 3.5 or 17.5 mg/kg once every 2 days for 5 weeks | Enhance immune function | IL-1↑, IL-6↑, TNF- | Wistar rats | [ |
| Ag conjugated to core nanobeads | 40–50 nm | Intradermally | Immunogenic | IFN- | H-2Kb C57BL/6 | [ |
|
| ||||||
| Magnetic Nanoparticles | ||||||
| Iron Oxide NP | 43 nm | Intratracheal instillation (4 or 20 | Activate immune response | IFN- | OVA-sensitized mice (BALB/c) | [ |
| Iron Oxide NP | 58.7 nm | Intravenously ≤10 mg iron/kg | Immunosuppression | IFN- | DTH mice (male BALB/c) | [ |
| Iron Oxide NP | 35 ± 14 nm | Intratracheally 4 × 500 | Immunosuppression | IgE↓, IL-4↓ | OVA-sensitized mice (BALB/c) |
[ |
| Intratracheally 4 × 100 | Hypersensitivity | IgE↑, IL-4↑ | ||||
| 147 ± 48 nm | Intratracheally 4 × 500 | Immunosuppression | IgE↓, IL-4↓ | |||
| Intratracheally 4 × 100 | No significant effect | N/A | ||||
|
| ||||||
| Nanoceria | ||||||
| Nanoceria | D: 8 nm | Oropharyngeal instillation of 10, 30, or 100 | Inflammation | TNF- | C57BL/6 |
[ |
| A: 44 m2/g | ||||||
| Nanoceria | 20 nm | Single intratracheal instillation at 0.15–7 mg/kg | Inflammation | NO↓, IL-12↑ | Specific pathogen-free male Sprague-Dawley (Hla: SD-CVF) rats | [ |
| Nanoceria | D: 20–30 nm | Intratracheal instillation at 50 and 150 m2/mouse | Inflammation | IL-1 | Female Wistar rats |
[ |
| A: 24.1 m2/g | ||||||
| Nanoceria | D: 55 nm | Inhalation of 641 mg/m3 for 24 h, 48 h, and 14 days | Inflammation | IL-1 | Wistar rats |
[ |
| A: 30–50 m2/g | ||||||
|
| ||||||
| Quantum Dots | ||||||
| CdTe NP | N/A | 1.6, 4, and 8 mg/L for 24 h | Immunosuppression | N/A |
| [ |
| CdS/CdTe NP | N/A | 5, 10 and 20 nm for 96 h | Immunosuppression | N/A | Juvenile rainbow trout | [ |
|
| ||||||
| Silica Nanoparticles | ||||||
| Amorphous silica NP | 30 and 70 nm | Intraperitoneal injection of 1 mg/mice | Inflammation | IL-5↑, IL-6↑, MCP-1↑, keratinocyte chemoattractant↑ | Female BALB/c |
[ |
| Amorphous silica NP modificated with carboxyl groups | 70 nm | Intraperitoneal injection of 1 mg/mice | Suppression of inflammation | N/A | ||
| Nonporous nanosilica NP | 15 nm | Intravenous injections at single dose at 50 mg/kg | Inflammation oxidative stress | ROS↑, TNF- | Male SD rats | [ |
|
| ||||||
| Polymer | ||||||
| Polystyrene NP | 50 nm | Intratracheal administration of 200 | Anti-inflammation immunosuppression | IL-4↓, IL-5↓, IL-13↓ | Allergen challenge mice | [ |
| Polystyrene beads (PSB) coupled with the immunodominant myelin proteolipid protein PLP139–151 epitope (PLP139–151-PSB) | 500 nm | intravenous injection of approximately 9 × 109 microparticles | T-cell tolerance | IL-17↓, INF- | Peptide-induced experimental autoimmune encephalomyelitis SJL/J mice | [ |
|
| ||||||
| Dendrimer | ||||||
| Pan-DR-binding epitope (PADRE)-derivatized-dendrimer (PDD) | N/A | Intravenous injection with 6.25 mg/kg/day of LAmB at a ratio of 10 : 1 (PDD : LAmB) for 10 days | enhanced adaptive immunity | IFN- | Female BALB/c mice inoculated intraperitoneally with metacyclic promastigotes of L. major | [ |
|
| ||||||
| Lipid Nanoparticles | ||||||
| cSLN-pDNA (a DNA vaccine harbouring the | 241 ± 12 nm | immunized in the right-hind footpad with 50 | Enhanced immunity | Ratio of IFN- |
| [ |
| MPLA : NLP | 6–25 nm | intraperitoneal injection ion of 1, 5, 10, 20 | Enhanced immunostimulatory | IL-6↑, TNF- | Female BALB/c mice | [ |
| CpG : NLP constructs | 6–25 nm | intraperitoneal injection ion of 10, 20, 40 or 80 | Enhanced immunostimulatory | IL-6↑, TNF- | Female BALB/c mice | [ |
| Pegylated liposomal doxorubicin (Doxil) | 85–100 nm | Infuse in accordance with the administration guideline of Doxil | Hypersensitivity reactions occurred in 45% of patients | N/A | Patients with solid tumors ( | [ |
Figure 2Multiassay score of the functional MWNT library. (a) Surface molecular compositions of combinatorial MWNT library members. (b) Findings from four protein (BSA, carbonic anhydrase, chymotrypsin, and hemoglobin) binding assays, cytotoxicity, and immune response assays (MWNT-induced NO release) at 50 μg/mL in THP-1 macrophages were ranked for all library members. The sum of their ranks was designated the multiassay score and is shown as vertical bars in the graph. Reprinted with permission from [124].
Figure 3Mechanisms involved in NPs-induced immunomodulation. The stimulation/suppression to immune system depends on the nature of NPs and results in different outcomes. NPs, nanoparticles; NF-κB, nuclear factor kappa B; TLR pathway: toll-like receptor pathway; APC, antigen-presenting cell; DCs, dendritic cells; MCs, mast cells; GM-CSF, granulocyte-macrophage colony-stimulating factor; Th0, type 0 T-helper lymphocyte; Th1, type 1 T-helper lymphocyte; Th2, type 2 T-helper lymphocyte; solid line with arrow, activate/release/induce; solid line with vertical dashes at ends, inhibit; dotted line, possible influence; broken line, polarization/differentiation.
Figure 4A schematic diagram elucidating the mechanisms responsible for GO-induced cytotoxicity to macrophages. Reprinted with permission from [144].